Salt Lake City, Utah – Doctors diagnosed Christopher Gregg, Ph.D., member of the Nuclear Control of Cell Growth and Differentiation Program at Huntsman Cancer Institute at the University of Utah and neuroscientist and professor of neurobiology and human genetics at the at the same institution, with stage 4 metastatic breast...
Latest News
DUBLIN – Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society (ERS), which include use of Acthar® Gel (repository corticotropin injection) therapy in the clinical management of certain patients with pulmonary sarcoidosis, published in European Respiratory Journal.[1] The treatment...
DUBLIN, Ireland — Mallinckrodt plc, a global specialty pharmaceutical company, recently announced the publication of findings from a cost analysis of TERLIVAZ® (terlipressin) for injection for adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function.This analysis assessed the treatment-related cost per patient response with TERLIVAZ plus albumin from...
DUBLIN, March 4, 2021 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safety of its investigational agent terlipressin in adults with hepatorenal syndrome type 1 (HRS-1). HRS-1 is an acute and life-threatening syndrome involving acute kidney failure...
CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threatening and acute form of advanced liver disease with high unmet needs and a poor prognosis — DUBLIN – Mallinckrodt Plc, a global biopharmaceutical company, today announced the publication of results from its pivotal Phase 3 CONFIRM...
Dublin — Mallinckrodt plc, (NYSE American: MNK) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today announced that Japan’s National Health Insurance (NHI) system has approved reimbursement for the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or -intolerant chronic graft versus host disease (cGvHD). “We are...
DUBLIN — Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced the presentation of 11 scientific abstracts with findings from the latest clinical and health economics research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function during the American...
Dublin — Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, announced that two scientific abstracts on the clinical and health economic outcomes of treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) will be presented at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)...
Dublin — Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, announced that an abstract highlighting results from a retrospective analysis evaluating the corticosteroid-sparing effect and reduction of corticosteroid burden of Acthar® Gel (repository corticotropin injection) therapy in patients with advanced sarcoidosis, has been selected for a poster presentation...
WUHAN, China and SAN DIEGO — Matthias Szabo Zarb, a Maltese college student, was diagnosed with Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON) two years ago, which led to a rapid deterioration in his visual acuity and inability to engage in normal activities. Through the National Alliance for Rare...